Terns Pharmaceuticals, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Terns Pharmaceuticals, Inc. | TERN - NASDAQ |
$15.00-$17.00 | $17.00 | $16.95 | 7.5 million | 2/5/2021 |
| JP Morgan, Goldman Sachs, Cowen | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2021-01-15 Terms Added 2021-02-01 | ||||||
Terns Pharmaceuticals, Inc. Quote & Chart - Click for current quote - TERN
IPO Boutique aggregates information on public companies and private companies, such as "TERN" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Terns Pharmaceuticals, Inc. (adapted from Terns Pharmaceuticals, Inc. prospectus):
They are a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "TERN" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.